Dudediligence.

Ocugen, Inc

OCGNNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$589,741

1 notice · 525,991 sh

Oct 2025 to Oct 2026

Reported ·

$25,830

0 sales · 1 buy

Oct 2025 to Jun 2026

The two figures cover different periods.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-09-09: Shankar Musunuri, Form 1442026-06-15: Johnson-Greene Treerita Essalima, bought
under a no plan named▼ sale▲ buysize is dollars

Form 144 notices, newest first

2026-09-09Shankar Musunuri, Chief Executive Officer$589,741
525,991 shplan 2026-06-05Form 4s on file end Jun 23144 ↗